title: The evolving role of lenalidomide in non-Hodgkin lymphoma.
abstract: Recent advances in the treatment of patients with non-Hodgkin lymphoma have driven a paradigm shift from standard chemotherapy to an ever-expanding choice of targeted agents and combinations. As an orally bioavailable immunomodulator with antineoplastic, immunologic, and antiproliferative activity in B-cell lymphoma, lenalidomide has emerged as one such option. Lenalidomide demonstrates clinically significant activity with a favorable safety profile as a single agent, as well as in combination therapy. Herein, we review accumulated clinical data on lenalidomide, with particular reference to patients with first-line and relapsed/refractory mantle cell lymphoma, indolent lymphoma, and diffuse large B-cell lymphoma.
authors.affiliation: a Section of Hematology and Oncology , the University of Chicago , Chicago , IL , USA ;
authors.forename: Natalie
authors.initials: N
authors.lastname: Galanina
authors.affiliation: b Division of Hematology/Oncology , Northwestern Medicine , Chicago , IL , USA ;|c Department of Hematology/Medical Oncology , Robert H. Lurie Comprehensive Cancer Center of Northwestern University , Chicago , IL , USA.
authors.forename: Adam
authors.initials: A
authors.lastname: Petrich
authors.affiliation: a Section of Hematology and Oncology , the University of Chicago , Chicago , IL , USA ;
authors.forename: Chadi
authors.initials: C
authors.lastname: Nabhan
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D056747:Immunomodulation / Q000187:drug effects; D000077269:Lenalidomide; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D007155:Immunologic Factors; D013792:Thalidomide; D000077269:Lenalidomide
keywords: Diffuse large B-cell lymphoma; indolent lymphoma; lenalidomide; mantle cell lymphoma; non-Hodgkin lymphoma